• Aroa Biosurgery named Michael Lynskey chief commercial officer on July 28, 2026, tasking him with leading global commercial growth.
• Lynskey brings 20+ years in advanced wound healing; he joins from Smith+Nephew, following earlier roles at Stryker, Johnson & Johnson.
• Mike Falcon was appointed general manager, US commercial, to lead the U.S. commercial organization as the company expands its presence.
• Falcon previously held commercial leadership roles at LifeNet Health; earlier positions included Biomet, Johnson & Johnson.
• Moves add senior leadership to support momentum in the Myriad portfolio, targeting increased opportunity for the Symphony outpatient product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aroa Biosurgery Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607280103PR_NEWS_USPR_____CN13561) on July 28, 2026, and is solely responsible for the information contained therein.